Journavx
Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion
Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development
Vertex COO Stuart Arbuckle to Retire as Company Launches Groundbreaking Pain Drug Journavx
Vertex Pharmaceuticals, Stuart Arbuckle, retirement, Journavx, non-opioid pain medication, FDA approval, acute pain treatment
FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades
Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative
FDA Approves Vertex’s Journavx: A Breakthrough Non-Opioid Pain Medication
Journavx, suzetrigine, Vertex Pharmaceuticals, FDA approval, non-opioid pain reliever, acute pain treatment, NaV1.8 inhibitor